Newsroom

Page Meta: of 101 press releases

Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary

Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy

Freeline Reports December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Freeline Receives Approval to Transfer to Nasdaq Capital Market

Freeline Reports Third Quarter 2022 Financial Results and Corporate Update

Freeline to Present at the Stifel Healthcare Conference

Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease

For all media enquiries please get in touch

media@freeline.life

Get in touch

+44 (0)1438 906870
contact@freeline.life

Follow us on our social channels